Male birth control pill may be ready soon

Attention men: The day may be coming soon when you can take your own birth control pill with no side effects, according to a study done by a group of scientists that includes a Texas A&M University researcher.

Qinglei Li, an assistant professor in Texas A&M's College of Veterinary Medicine & Biomedical Sciences, is part of a team of researchers led by Martin Matzuk at Baylor College of Medicine and James Bradner at Dana-Farber Cancer Institute who made the discovery, and their work is published in the journal Cell.

Working on mice, the team found that a compound called JQ1 acts as an inhibitor to sperm production and also sperm mobility.

"Both of these are needed for fertility, but JQ1 prevents both," Li says of the findings.

"It stopped the sperm production very dramatically. More good news is that there appear to be no side effects whatsoever. Once the JQ1 was no longer given to the mice, they were back to their normal reproduction rates, and it did not affect mating behavior or the health of the offspring."

Though the mice were given injections, the team believes that a pill could eventually be developed for the same results.

A male contraceptive pill has been talked about for decades, but so far none has been successfully created despite a strong demand.

While many men might be reluctant to take out the trash or ask for directions if they are lost, recent studies have shown that about 70 percent of men would be willing to take a birth control pill if it were available.

One drawback to many female contraceptives is that they sometimes interfere with hormones, especially estrogen. But Li says the team is confident that JQ1 does not affect testosterone levels in men, and appears to have no other side effects as well.

As with many discoveries, the JQ1 compound appears to have come about by accident.

It was originally used for anti-cancer treatments, but researchers found it was also an excellent compound in controlling fertility.

"This is an exciting step in male contraception," Li adds.

"A compound with more specificity will be needed before clinical trials can be done for humans. It does not mean a male birth control just yet, but it is a great step forward in that direction."

About Research at Texas A&M University
As one of the world's leading research institutions, Texas A&M is in the vanguard in making significant contributions to the storehouse of knowledge, including that of science and technology. Research conducted at Texas A&M represents an annual investment of more than $700 million. That research creates new knowledge that provides basic, fundamental and applied contributions resulting in many cases in economic benefits to the state, nation and world.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...